Skip to main content

Table 3 Summary of Weight Outcomes

From: Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis

  Weight Loss ≥ 2 kg Weight gain ≥ 1 kg
  At any time Sustained to endpoint At any time Sustained to endpoint
Nizatidine study
(n = 67)
20.9% (n = 14) 7.5% (n = 5) 70.2% (n = 47) 59.7% (n = 40)
Sibutramine study(n = 42) 42.9% (n = 18) 26.2% (n = 11) 42.9% (n = 18) 19.1% (n = 8)
Amantadine study(n = 48) 39.6% (n = 19) 33.3% (n = 16) 56.3% (n = 27) 37.5% (n = 18)
  1. Only patients with at least 1 post-baseline measurement are included.